This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
by Zacks Equity Research
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
CRMDPositive Net Change KNSAPositive Net Change IMVTPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
by Zacks Equity Research
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
REGNPositive Net Change SNYPositive Net Change ADPTPositive Net Change AKROPositive Net Change
pharmaceuticals
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
by Zacks Equity Research
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
AZNPositive Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
by Kinjel Shah
Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.
SNYPositive Net Change BMYPositive Net Change NVONegative Net Change TEVANegative Net Change
pharmaceuticals
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
by Sundeep Ganoria
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
BIIBPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris
by Zacks Equity Research
CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.
LLYPositive Net Change CHDPositive Net Change VTRSPositive Net Change
pharmaceuticals
Insider Watch: 3 CEOs Buying the Dip
by Derek Lewis
Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?
LLYPositive Net Change CHDPositive Net Change VTRSPositive Net Change
medical pharmaceuticals
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
by Zacks Equity Research
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
AZNPositive Net Change GSKPositive Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs medical pharmaceuticals
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
by Kanishka Das
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change
pharmaceuticals
J&J Gears Up for Some Key New Drug Approvals and Launches
by Kinjel Shah
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
AZNPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
by Zacks Equity Research
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
BMYPositive Net Change CYTKPositive Net Change CRMDPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
by Zacks Equity Research
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
CRMDPositive Net Change EDITPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
by Zacks Equity Research
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
NVSPositive Net Change RHHBYNegative Net Change ARWRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: Eli Lilly, Eaton and Interactive Brokers
by Zacks Equity Research
Eli Lilly, Eaton, and Interactive Brokers post standout Q2 results, with booming sales, raised guidance, and record-breaking growth.
LLYPositive Net Change ETNPositive Net Change IBKRPositive Net Change
pharmaceuticals
These 3 Companies are Seeing Supercharged Sales Growth
by Derek Lewis
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
LLYPositive Net Change ETNPositive Net Change IBKRPositive Net Change
artificial-intelligence earnings finance pharmaceuticals
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
by Sundeep Ganoria
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
by Ahan Chakraborty
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
RHHBYNegative Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
by Kinjel Shah
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
BIIBPositive Net Change JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
GSK Adds Around $5B in a Month: Here's How to Play the Stock
by Kinjel Shah
GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.
GSKPositive Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
by Abhinab Dasgupta
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.
FASTPositive Net Change TMOPositive Net Change TSCOPositive Net Change ORCLNegative Net Change MTZPositive Net Change LPGNegative Net Change LITEPositive Net Change NTLANegative Net Change FSBWNegative Net Change CBREPositive Net Change PHARNegative Net Change
computers pharmaceuticals
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
by Zacks Equity Research
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
SNYPositive Net Change ADPTPositive Net Change AKROPositive Net Change ALGSPositive Net Change
pharmaceuticals
Pfizer's Golden Cross Signals Strength: How to Play the Stock
by Kinjel Shah
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
by Ahan Chakraborty
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
by Zacks Equity Research
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
ALNYNegative Net Change RHHBYNegative Net Change CRMDPositive Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals